New biotech from Alexis Borisy will test Merck KGaA, Blueprint cancer drug combo in bid to fulfill Gleevec promise
Alexis Borisy and Ben Auspitz want to be intelligent with their latest biotech, not “stupid.”
That’s in the words of Borisy, the repeat biotech entrepreneur behind the likes of Blueprint Medicines and EQRx. He and business partner Auspitz, a long-time industry investor at F-Prime Capital, want to bring together “intelligently designed” cancer drugs, hence their startup’s name: IDRx.
In launching their latest biotech, with a $122 million Series A, the duo believes it’s brought together two drugs that can be “best in class” as a combination therapy for certain cancers. At the heart of their new company is an old venture: Blueprint. IDRx has secured the license to a Blueprint asset and a Merck KGaA asset, with both companies retaining equity stakes in the startup in exchange for the transfer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.